"Tobacco control efforts are having a major impact on Americans' health, a new analysis of lung-cancer data suggests. The rate of new lung cancer cases decreased among men and women in the United States from 2005 to 2009, according to a re"...
- Patient Information:
Details with Side Effects
Nonsquamous Non-Small Cell Lung Cancer – Combination with Cisplatin
Nonsquamous Non-Small Cell Lung Cancer – Maintenance
ALIMTA is indicated for the maintenance treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
Nonsquamous Non-Small Cell Lung Cancer – After Prior Chemotherapy
ALIMTA is indicated as a single-agent for the treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy.
ALIMTA in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.
Limitations of Use
ALIMTA is not indicated for the treatment of patients with squamous cell non-small cell lung cancer. [see Clinical Studies]
DOSAGE AND ADMINISTRATION
Combination Use with Cisplatin for Nonsquamous Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
The recommended dose of ALIMTA is 500 mg/m² administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m² infused over 2 hours beginning approximately 30 minutes after the end of ALIMTA administration. See cisplatin package insert for more information.
Single-Agent Use as Maintenance Following First-Line Therapy, or as a Second-Line Therapy
The recommended dose of ALIMTA is 500 mg/m² administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.
Premedication Regimen and Concurrent Medications
Instruct patients to initiate folic acid 400 mcg to 1000 mcg orally once daily beginning 7 days before the first dose of ALIMTA. Continue folic acid during the full course of therapy and for 21 days after the last dose of ALIMTA [see WARNINGS AND PRECAUTIONS].
Administer vitamin B12 1 mg intramuscularly 1 week prior to the first dose of ALIMTA and every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with ALIMTA [see WARNINGS AND PRECAUTIONS].
Administer dexamethasone 4 mg by mouth twice daily the day before, the day of, and the day after ALIMTA administration [see WARNINGS AND PRECAUTIONS].
Laboratory Monitoring and Dose Reduction/Discontinuation Recommendations
Complete blood cell counts, including platelet counts, should be performed on all patients receiving ALIMTA. Patients should be monitored for nadir and recovery, which were tested in the clinical study before each dose and on days 8 and 15 of each cycle. Patients should not begin a new cycle of treatment unless the ANC is ≥ 1500 cells/mm³, the platelet count is ≥ 100,000 cells/mm³, and creatinine clearance is ≥ 45 mL/min. Periodic chemistry tests should be performed to evaluate renal and hepatic function [see WARNINGS AND PRECAUTIONS].
Dose Reduction Recommendations
Dose adjustments at the start of a subsequent cycle should be based on nadir hematologic counts or maximum nonhematologic toxicity from the preceding cycle of therapy. Treatment may be delayed to allow sufficient time for recovery. Upon recovery, patients should be retreated using the guidelines in Tables 1-3, which are suitable for using ALIMTA as a single-agent or in combination with cisplatin.
Table 1: Dose Reduction for ALIMTA (single-agent or in
combination) and Cisplatin – Hematologic Toxicities
|Nadir ANC < 500/mm³ and nadir platelets ?50,000/mm³ .||75% of previous dose (pemetrexed and cisplatin).|
|Nadir platelets < 50,000/mm³ without bleeding regardless of nadir ANC.||75% of previous dose (pemetrexed and cisplatin).|
|Nadir platelets < 50,000/mm³ with bleedinga, regardless of nadir ANC.||50% of previous dose (pemetrexed and cisplatin).|
|aThese criteria meet the CTC version 2.0 (NCI 1998) definition of ≥ CTC Grade 2 bleeding.|
If patients develop nonhematologic toxicities (excluding neurotoxicity) ≥ Grade 3, treatment should be withheld until resolution to less than or equal to the patient's pre-therapy value. Treatment should be resumed according to guidelines in Table 2.
Table 2: Dose Reduction for
ALIMTA (single-agent or in combination) and Cisplatin – Nonhematologic
|Dose of ALIMTA (mg/m²)||Dose of Cisplatin (mg/m²)|
|Any Grade 3 or 4 toxicities except mucositis||75% of previous dose||75% of previous dose|
|Any diarrhea requiring hospitalization (irrespective of Grade) or Grade 3 or 4 diarrhea||75% of previous dose||75% of previous dose|
|Grade 3 or 4 mucositis||50% of previous dose||100% of previous dose|
|aNCI Common Toxicity Criteria (CTC).
bExcluding neurotoxicity (see Table 3).
In the event of neurotoxicity, the recommended dose adjustments for ALIMTA and cisplatin are described in Table 3. Patients should discontinue therapy if Grade 3 or 4 neurotoxicity is experienced.
Table 3: Dose Reduction for
ALIMTA (single-agent or in combination) and Cisplatin – Neurotoxicity
|CTC Grade||Dose of ALIMTA (mg/m²)||Dose of Cisplatin (mg/m²)|
|0-1||100% of previous dose||100% of previous dose|
|2||100% of previous dose||50% of previous dose|
ALIMTA therapy should be discontinued if a patient experiences any hematologic or nonhematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.
Renally Impaired Patients
In clinical studies, patients with creatinine clearance ≥ 45 mL/min required no dose adjustments other than those recommended for all patients. Insufficient numbers of patients with creatinine clearance below 45 mL/min have been treated to make dosage recommendations for this group of patients [see CLINICAL PHARMACOLOGY]. Therefore, ALIMTA should not be administered to patients whose creatinine clearance is < 45 mL/min using the standard Cockcroft and Gault formula (below) or GFR measured by Tc99m-DTPA serum clearance method:
|Males:||(weight in kg) x (140 – age)|
|(72) x serum creatinine (mg/100 mL)|
|Females||Estimated creatinine clearance for males × 0.85|
Caution should be exercised when administering ALIMTA concurrently with NSAIDs to patients whose creatinine clearance is < 80 mL/min [see DRUG INTERACTIONS].
Preparation and Administration Precautions
As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions of ALIMTA. The use of gloves is recommended. If a solution of ALIMTA contacts the skin, wash the skin immediately and thoroughly with soap and water. If ALIMTA contacts the mucous membranes, flush thoroughly with water. Several published guidelines for handling and disposal of anticancer agents are available [see REFERENCES].
ALIMTA is not a vesicant. There is no specific antidote for extravasation of ALIMTA. To date, there have been few reported cases of ALIMTA extravasation, which were not assessed as serious by the investigator. ALIMTA extravasation should be managed with local standard practice for extravasation as with other non-vesicants.
Preparation for Intravenous Infusion Administration
- Use aseptic technique during the reconstitution and further dilution of ALIMTA for intravenous infusion administration.
- Calculate the dose of ALIMTA and determine the number of vials needed. Vials contain either 100 mg or 500 mg of ALIMTA. The vials contain an excess of ALIMTA to facilitate delivery of label amount.
- Reconstitute each 100-mg vial with 4.2 ml of 0.9% Sodium Chloride Injection (preservative free). Reconstitute each 500-mg vial with 20 mL of 0.9% Sodium Chloride Injection (preservative free). Reconstitution of either size vial gives a solution containing 25 mg/mL ALIMTA. Gently swirl each vial until the powder is completely dissolved. The resulting solution is clear and ranges in color from colorless to yellow or green-yellow without adversely affecting product quality. The pH of the reconstituted ALIMTA solution is between 6.6 and 7.8. FURTHER DILUTION IS REQUIRED.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulate matter is observed, do not administer.
- An appropriate quantity of the reconstituted ALIMTA solution must be further diluted into a solution of 0.9% Sodium Chloride Injection (preservative free), so that the total volume of solution is 100 ml. ALIMTA is administered as an intravenous infusion over 10 minutes.
- Chemical and physical stability of reconstituted and infusion solutions of ALIMTA were demonstrated for up to 24 hours following initial reconstitution, when stored refrigerated. When prepared as directed, reconstitution and infusion solutions of ALIMTA contain no antimicrobial preservatives. Discard any unused portion.
Reconstitution and further dilution prior to intravenous infusion is only recommended with 0.9% Sodium Chloride Injection (preservative free). ALIMTA is physically incompatible with diluents containing calcium, including Lactated Ringer's Injection, USP and Ringer's Injection, USP and therefore these should not be used. Coadministration of ALIMTA with other drugs and diluents has not been studied, and therefore is not recommended. ALIMTA is compatible with standard polyvinyl chloride (PVC) administration sets and intravenous solution bags.
Dosage Forms And Strengths
ALIMTA, pemetrexed for injection, is a white to either light-yellow or green-yellow lyophilized powder available in sterile single-use vials containing 100 mg or 500 mg pemetrexed.
ALIMTA, pemetrexed for injection, is available in sterile single-use vials containing 100 mg pemetrexed. NDC 0002-7640-01 (VL7640): single-use vial with ivory flip-off cap individually packaged in a carton. ALIMTA, pemetrexed for injection, is available in sterile single-use vials containing 500 mg pemetrexed. NDC 0002-7623-01 (VL7623): single-use vial with ivory flip-off cap individually packaged in a carton.
Storage and Handling
ALIMTA, pemetrexed for injection, should be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].
Chemical and physical stability of reconstituted and infusion solutions of ALIMTA were demonstrated for up to 24 hours following initial reconstitution, when stored refrigerated, 2-8°C (36-46°F). When prepared as directed, reconstituted and infusion solutions of ALIMTA contain no antimicrobial preservatives. Discard unused portion [see DOSAGE AND ADMINISTRATION].
ALIMTA is not light sensitive.
1. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. NIOSH Alert 2004-165.
2. OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html
3. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63:1172-1193.
4. Polovich, M., White, J. M., & Kelleher, L. O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA. Revised September 2013
Last reviewed on RxList: 9/27/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Alimta Information
Alimta - User Reviews
Alimta User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.